E I Du Pont De Nemours And Co  

(Public, NYSE:DD)   Watch this stock  
Find more results for DD
77.49
-0.31 (-0.40%)
Feb 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 76.81 - 77.80
52 week 57.76 - 78.40
Open 77.70
Vol / Avg. 1.72M/2.34M
Mkt cap 66.74B
P/E 27.18
Div/yield 0.38/1.96
EPS 2.85
Shares 864.57M
Beta 1.68
Inst. own 73%
Jan 24, 2017
Q4 2016 E I du Pont de Nemours and Co Earnings Release
Jan 24, 2017
Q4 2016 E I du Pont de Nemours and Co Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 4.78% 10.18%
Operating margin 3.91% 12.62%
EBITD margin - 19.93%
Return on average assets 2.45% 6.21%
Return on average equity 10.45% 25.61%
Employees 46,000 -
CDP Score - 99 B

Address

974 Centre Rd
WILMINGTON, DE 19805-1269
United States - Map
+1-302-7741000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

E. I. du Pont de Nemours and Company (DuPont) is a science and technology-based company. The Company consists of over 10 businesses aggregated into six segments: Agriculture, Electronics & Communications, Industrial Biosciences, Nutrition & Health, Performance Materials and Safety & Protection. Its products include corn hybrids and soybean varieties, herbicides, fungicides and insecticides in Agriculture segment; photopolymers and electronic materials in Electronics & Communications segment; enzymes and bio-based materials in Industrial Biosciences segment; cultures, emulsifiers, texturants, natural sweeteners and soy-based food ingredients in Nutrition & Health segment; engineering polymers, packaging and industrial polymers, films and elastomers in Performance Materials segment, and nonwovens, aramids and solid surfaces in Safety & Protection segment. It is also involved in other businesses, such as pre-commercial programs, nonaligned businesses and pharmaceuticals in other.

Officers and directors

Edward D. Breen Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Nicholas Charles Fanandakis Chief Financial Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
James C. Collins Jr. Executive Vice President
Age: 53
Bio & Compensation  - Reuters
C. Marc Doyle Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Stacy L. Fox Senior Vice President, General Counsel
Age: 62
Bio & Compensation  - Reuters
Benito Cachinero-Sanchez Senior Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Douglas W. Muzyka Senior Vice President and Chief Science & Technology Officer
Age: 61
Bio & Compensation  - Reuters
Lamberto Andreotti Independent Director
Age: 65
Bio & Compensation  - Reuters
Robert A. Brown Independent Director
Age: 64
Bio & Compensation  - Reuters
Alexander M. Cutler Independent Director
Age: 64
Bio & Compensation  - Reuters